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CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on 
agent choice. A systematic review and meta-analysis
Concetta E. Onesti a,b and Guy Jerusalem a
aMedical Oncology Department, CHU Liège Sart Tilman and Liège University, Liège, Belgium; bLaboratory of Human Genetics, GIGA Research 
Center, Liège, Belgium
ABSTRACT
Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly chan-
ged therapeutic algorithms, with three drugs currently approved.
Areas covered: Here, we analyze the toxicity profiles of palbociclib, ribociclib, and abemaciclib 
through a systematic review and meta-analysis. Palbociclib and ribociclib showed high rates of 
hematological toxicity, primarily neutropenia, and were associated with a low rate of severe infec-
tions. Abemaciclib was associated with a high rate of gastrointestinal toxicities, primarily diarrhea, of 
grade 1–2 in most cases. Ribociclib was associated with a high rate of hepatic, and respiratory toxicity 
and with QTc prolongation. The toxicity rate of ribociclib was higher in metastatic patients than non- 
metastatic patients, with approximately 33% more grade 3–4 toxicities and 21% more grade 3–4 
neutropenic events. A 5% higher risk of diarrhea was observed in postmenopausal patients. Pre- 
treated patients did not show a higher toxicity rate for palbociclib/ribociclib than previously untreated 
patients, while a 26% higher risk of any grade neutropenia and 6% higher risk of grade 3–4 diarrhea 
were observed with abemaciclib.
Expert opinion: Considering the similar efficacies and indications of palbociclib, ribociclib, and abe-
maciclib, the evaluation of their toxicity profiles may facilitate treatment choice.
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With the advent of personalized medicine, new molecular 
targeted therapies have recently been introduced into clinical 
practice. Among them, cyclin-dependent kinases 4 and 6 
(CDK4/6) in breast cancer have increasing importance, with 
the approval in recent years of three CDK4/6 inhibitors: palbo-
ciclib, ribociclib, and abemaciclib [1–5].
CDK4/6 are involved in regulation of the cell cycle and, in 
particular, in the transition from G1 to S phase [6]. In particu-
lar, D cyclins form a complex with CDK4 or 6, which becomes 
active and phosphorylates retinoblastoma protein (RB), 
a negative cell cycle inhibitor. When phosphorylated, RB 
releases the transcriptional factor EF2, which in turn regulates 
the expression of genes involved in cell cycle progression [6]. 
The cyclin D-CDK4/6-RB pathway is frequently disrupted in 
cancer, notably in breast cancer, with some differences 
between the subtypes. The cyclin D1 gene (CCND1) is ampli-
fied in approximately 15% of breast cancers, primarily luminal 
types (58% in luminal B and 29% in luminal A) but also in 
HER2-enriched subtypes (38% of cases) [7–9]. Moreover, CDK4 
gain has been observed in approximately 25% of luminal 
B cancers and in 14% of luminal A, while RB loss is present 
in 20% of basal-like tumors, leading to CDK4/6 inhibitor resis-
tance [7,10]. Upstream oncogenic signaling leads to the acti-
vation of the cyclin D1–CDK4/6 complex and estrogens induce 
the expression of cyclin D1, causing this pathway to be one of 
the major contributors to tumor progression in hormone 
receptor (HR)-positive breast cancer [11–13].
Breast cancer is the most common cancer and the leading 
cause of cancer-related death in women worldwide [14]. The 
majority of patients, approximately 70%, are HR-positive and 
HER2-negative [15]. In this group of patients, a benefit with 
CDK4/6 inhibitors has been observed in several clinical trials, 
leading to their approval for the treatment of metastatic tumors 
in combination with endocrine therapy (ET) [13]. In other set-
tings, primarily HER2-positive or non-metastatic patients, the 
use of these drugs is currently being explored [16–22].
Actually, all three CDK4/6 inhibitors are approved in com-
bination with aromatase inhibitors (AI) or fulvestrant for treat-
ing metastatic HR-positive/HER2-negative breast cancer (FDA 
and EMA approval), while abemaciclib is also approved as 
a monotherapy (FDA approval). Their mechanism of action 
and efficacy are similar, with some differences in their toxicity 
profiles. In this systematic review and meta-analysis, we 
explored the safety profiles of palbociclib, ribociclib, and abe-
maciclib in clinical trials and as in real-life clinical cohorts.
2. Methods
2.1. Literature search and data extraction
A systematic literature search was performed on May 24, 2020, 
in MEDLINE using the following keywords: ‘palbociclib breast 
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cancer,’ ‘ribociclib breast cancer’ and ‘abemaciclib breast can-
cer.’ All publications were collected and sorted by a medical 
oncologist (OCE). Full-text analysis and data extraction were 
performed by a reviewer (OCE) and verified by a second 
reviewer (GJ).
The following inclusion criteria were used to select articles 
for the final analysis: clinical studies on breast cancer patients, 
regardless of stage of the disease or the treatment line; clinical 
studies using currently approved doses for palbociclib 
(125 mg QD d1-21 q28), ribociclib (600 mg QD d1-21 q28) or 
abemaciclib (150 mg BID in combination with ET or 200 mg 
BID in monotherapy); studies in which CDK4/6 inhibitors were 
administered in combination with ET or as a monotherapy; 
and studies for which safety data of at least one adverse event 
were reported in the article in the form of percentage or 
number of patients reporting each toxicity. All of the following 
types of studies were included in the analysis: Phase I, Phase II, 
Phase III trials, expanded access programme (EAP), compassio-
nate use programme and retrospective analysis. Exclusion 
criteria were as follows: studies not published in extenso; 
meta-analyses and literature reviews; studies where the admi-
nistered dose of palbociclib, ribociclib, or abemaciclib was not 
that currently approved; studies in which CDK4/6 inhibitors 
were administered in concomitance of treatment other than 
ET or with radiotherapy, and studies where adverse effects 
were not reported.
The following data were included in the database: the total 
number of patients in the CDK4/6 arm; the stage of disease of 
patients included in the study (metastatic/non-metastatic); 
menopausal status; whether previous treatment had been 
administered; the number of events for any grade and grade 
3–4 for toxicities of all types, neutropenia, leucopoenia, anemia, 
thrombocytopenia, infection, febrile neutropenia, AST and ALT 
increase, renal toxicity, diarrhea, vomiting, nausea, constipation, 
abdominal pain, stomatitis, dysgeusia, decreased appetite, fati-
gue, arthralgia, back pain, dizziness, headache, rash, hot flushes, 
pruritus, respiratory impairment, alopecia, thromboembolic 
event, and QTc prolongation. The number of severe adverse 
events (SAEs) and of toxic deaths was also collected.
Data extraction was performed according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines [23].
2.2. Statistical analysis
A one-sample proportion was used to obtain the pooled effect 
for each toxicity. Random and the fixed effect models were 
used to perform the analysis. Absolute risk (AR) and the 95% 
confidence interval (CI) were used to present the results. In the 
tables and in figures both random and fixed effect models are 
presented, while in the text, we presented results derived from 
the random effect model, which better fit our data considering 
the heterogeneity among the studies. Heterogeneity was 
assessed by means of the Higgins’ I2 statistic. The quality of 
each publication was assessed using the Cochrane risk of bias 
tools, Rob-2 for randomized trials, and ROBINS-1 for nonran-
domized trials [24,25]. Publication bias was assessed with 
Egger’s test.
In the first part of the analysis, data derived from palboci-
clib, ribociclib, and abemaciclib were analyzed separately. In 
the second part of the analysis, we analyzed data derived from 
metastatic and non-metastatic patients, from patients in pre- 
and post-menopausal status, and from previously untreated 
and in pre-treated patients.




A systematic literature search performed in MEDLINE identi-
fied 1024 records. A screening procedure identified 40 articles 
(Figure 1), that were included in the final database after 
exclusion of duplicates (323), non-clinical studies (612), post- 
hoc or subgroup analysis (17), articles in which toxicities were 
not detailed (16), combination with drugs other than endo-
crine therapy (8), study design (3), and report on other cancer 
types (2). Ultimately, 27 studies were included in the meta- 
analysis.
The type of study, the population included, the treatment 
arm, and the number of patients in the CDK4/6-inhibitor arm 
are summarized in the Table 1. The quality of each trial was 
assessed according to the Cochrane risk of bias tools and is 
reported in Table 1.
3.2. Safety results with palbociclib, ribociclib and 
abemaciclib
The absolute number of events for each toxicity was collected 
for all the studies and analyzed separately for palbociclib, 
ribociclib, and abemaciclib.
Of the 27 studies included in the meta-analysis, 20 were on 
palbociclib, including 2683 patients, 4 on ribociclib, including 
1203 patients, and 3 on abemaciclib, including 906 patients.
Overall, for Palbociclib, 2 Phase III trials, 9 Phase II, 1 Phase I, 
1 EAP, 2 compassionate use programs, and 5 retrospective 
studies were analyzed; for ribociclib, 3 Phase III and 1 Phase 
II trials were analyzed; and for abemaciclib, 2 Phase III and 1 
Phase II trials were analyzed [18,19,22,26–58].
Publication bias was assessed with Egger’s test and is 
reported in Tables 2 and 3.
Article highlights
● Palbociclib and ribociclib show a high rate of neutropenia, that is 
rapidly reversible and associated with a low rate of infection.
● Abemaciclib shows a high rate of gastrointestinal side effects, such as 
diarrhea and abdominal pain, which, although of low grade, can have 
a great impact on the patient quality of life.
● CDK4/6 inhibitors show a higher rate of toxicity in metastatic 
patients, probably due to their poorer general condition but also to 
the longer duration of treatment, than non-metastatic patients.
● Palbociclib and ribociclib do not seem to be more toxic in pretreated 
patients than in previously untreated patients, while abemaciclib 
seems to be associated with a higher rate of any grade neutropenia 
and grade 3-4 diarrhea.
● The toxicity profiles of palbociclib and ribociclib in pre- and post-
menopausal patients are similar, with only a slight increase observed 
in the risk of diarrhea in postmenopausal patients.
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The three drugs were comparable in terms of any grade 
toxicities, with an absolute risk (AR) of 0.981 (95% CI 0.972–-
0.987; p < 0.0001) for palbociclib, 0.984 (95% CI 0.971–0.991; 
p < 0.0001) for ribociclib, and 0.979 (95% CI 0.966–0.987; 
p < 0.0001) for abemaciclib (Table 2). Abemaciclib showed 
a lower risk of grade 3–4 toxicities, with an AR of 0.592 (95% 
CI 0.557–0.626; p < 0.0001) compared to an AR of 0.763 (95% 
CI 0.634–0.857; p < 0.0001) for palbociclib and an AR of 0.739 
(95% CI 0.629–0.825; p < 0.0001) for ribociclib (Table 3).
The most common toxicities were hematologic for palbo-
ciclib and ribociclib and gastrointestinal for abemaciclib (Table 
2 and Table 3).
We observed an AR of 0.854 (95% CI 0.800–0.895; 
p < 0.0001) for any grade and 0.605 (95% CI 0.543–0.664; 
p 0.001) for grade 3–4 neutropenia with palbociclib; an AR of 
0.760 (95% CI 0.702–0.810; p < 0.0001) and 0.586 (95% CI 
0.531–0.638; p 0.002) for any grade and grade 3–4 neutrope-
nia, respectively, with ribociclib; and 0.605 (95% CI 0.400–-
0.779; p 0.317) and 0.225 (95% CI 0.175–0.283; p < 0.0001) 
for any grade and grade 3–4 neutropenia, respectively, with 
abemaciclib (Figure 2 and Figure 3). Considering the 
publication bias found for any grade neutropenia in palboci-
clib studies (Egger’s test p 0.006), presumably due to the 
inclusion of retrospective studies, a second analysis was per-
formed including only Phase I–III trials, which found similar 
results. Twelve studies with 1621 patients were analyzed, yeld-
ing an AR with a random effect model of 0.857 (95% CI 0.-
777–0.912; p < 0.0001; I2 91%), without publication bias 
(Egger’s test p 0.107). Despite the high rate of neutropenia, 
primarily for palbociclib and ribociclib compared to abemaci-
clib, the rate of infection was low, with some differences 
observed between the three drugs: AR 0.313 (95% CI 0.205–-
0.446; p 0.007), AR 0.541 (95% CI 0.498–0.585; p 0.064), AR 
0.385 (95% CI 0.329–0.443; p < 0.0001) for any grade infection 
with palbociclib, ribociclib, and abemaciclib, respectively; AR 
0.049 (95% CI 0.034–0.070; p < 0.0001), AR 0.056 (95% CI 
0.037–0.082; p < 0.0001) and AR 0.038 (95% CI 0.023–0.063; 
p < 0.0001) for grade 3–4 infection with palbociclib, ribociclib, 
and abemaciclib, respectively. Considering only Phase I–III 
trials for palbociclib with a random effect model, we obtained 
an AR of 0.361 (95% CI 0.228–0.519; p 0.083; I2 93%; Egger’s 
test p 0.091) for any grade infection and an AR of 0.055 (95% 
Figure 1. Consort diagram for article selection according to PRISMA guidelines.















































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































EXPERT REVIEW OF ANTICANCER THERAPY 289
CI 0.037–0.080; p < 0.0001; I2 28%; Egger’s test p 0.010) for 
grade 3–4 infection. Febrile neutropenia was observed at 
a higher rate in the palbociclib group (AR 0.023, 95% CI 0.-
017–0.031, p < 0.0001) than in the ribociclib (AR 0.010, 95% CI 
0.005–0.021, p < 0.0001) and abemaciclib (AR 0.008, 95% CI 
0.002–0.032, p < 0.0001) groups. Considering only Phase I–III 
trials, the AR with a random effect model for febrile neutro-
penia with palbociclib was 0.016 (95% CI 0.010–0.025; 
p < 0.0001; I2 0%; Egger’s test p 0.236).
Concerning gastrointestinal toxicities, the most common 
was diarrhea, with ARs for any grade toxicity of 0.144 (95% 
CI 0.103–0.197, p < 0.0001), 0.258 (95% CI 0.181–0.355, 
p < 0.0001) and 0.853 (95% CI 0.809–0.888, p < 0.0001) for 
palbociclib, ribociclib and abemaciclib, respectively (Figure 4). 
Considering the publication bias found for any grade diarrhea 
in palbociclib studies (Egger’s test p 0.019), phase I–III trials 
alone (9 studies with 1465 patients) were analyzed, revealing 
an AR with a random effect model of 0.183 (95% CI 0.141–-
0.233; p < 0.0001; I2 75%; Egger’s test p 0.003). However, 
diarrhea observed in the abemaciclib group was of low 
grade in the majority of cases. In fact, the AR of grade 3–4 
diarrhea was 0.011 (95% CI 0.007–0.018, p < 0.0001) for pal-
bociclib, 0.015 (95% CI 0.008–0.027, p < 0.0001) for ribociclib 
and 0.135 (95% CI 0.092–0.192, p < 0.0001) for abemaciclib 
(Figure 5).
Abemaciclib also showed a higher risk of other gastroin-
testinal toxicities, primarily nausea (AR for any grade toxicity 
0.195, 0.382 and 0.420 for palbociclib, ribociclib, and abema-
ciclib, respectively), decreased appetite (AR for any grade 
toxicity 0.140, 0.137 and 0.265 for palbociclib, ribociclib and 
abemaciclib, respectively) and abdominal pain (AR for any 
grade toxicity 0.082 for palbociclib and 0.300 for abemaciclib, 
insufficient data reported to perform the meta-analysis for 
ribociclib).
Figure 2. Absolute risk for any grade neutropenia for palbociclib, ribociclib and abemaciclib.
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Renal alterations were also more frequent in the abemaci-
clib group, with an AR for any grade toxicity of 0.076, 0.070, 
and 0.261 for palbociclib, ribociclib, and abemaciclib, respec-
tively. In the majority of studies, the parameter reported for 
renal function evaluation is the increase of creatinine level, 
with the exception of three studies, one for palbociclib, and 
two for ribociclib, in which the parameter evaluated was not 
specified in the articles [45,49–52].
Ribociclib showed a higher risk of hepatic toxicity, than 
palbociclib and abemaciclib, primarily for grade 3–4 adverse 
events: AR for grade 3–4 ALT increase with palbociclib 0.034, 
0.097 for ribociclib and 0.046 for abemaciclib; and AR for AST 
increase of 0.029, 0.054, and 0.029 for palbociclib, ribociclib, 
and abemaciclib, respectively.
Any grade arthralgia was also more frequently observed in 
patients treated with ribociclib: AR 0.185, 0.288, and 0.142 for 
palbociclib, ribociclib, and abemaciclib, respectively.
Ribociclib exhibited a higher absolute risk compared to 
palbociclib for respiratory toxicity (AR for any grade respiratory 
toxicity 0.311 and 0.144; AR for grade 3–4 respiratory toxicity 
0.020 and 0.012 for ribociclib and palbociclib, respectively) and 
QTc prolongation (AR for any grade QTc prolongation 0.073 
and 0.008; AR for grade 3–4 QTc prolongation 0.019 and 0.002 
for ribociclib and palbociclib, respectively). Insufficient data 
were available for abemaciclib to perform the meta-analysis.
Conversely, a lower risk of any grade fatigue was observed 
in patients receiving ribociclib: AR 0.452, 0.283, and 0.397 for 
palbociclib, ribociclib, and abemaciclib, respectively.
Figure 3. Absolute risk for grade 3–4 neutropenia for palbociclib, ribociclib and abemaciclib.
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ARs for SAEs of 0.097 (95% CI 0.067–0.140; p < 0.0001; I2 
76%; Egger’s test 0.013), of 0.195 (95% CI 0.133–0.276; 
p < 0.0001; I2 87%; Egger’s test 0.215) and of 0.246 (95% CI 
0.215–0.280; p < 0.0001; I2 22%; Egger’s test p 0.939) for 
palbociclib, ribociclib, and abemaciclib, respectively, were 
observed.
Toxic death was a rare event, with an AR of 0.004 (95% CI 
0.002–0.011; p < 0.0001; I2 0%; Egger’s test 0.332) for palboci-
clib, 0.003 (95% CI 0.001–0.009; p < 0.0001; I2 0%; Egger’s test 
0.881) for ribociclib and 0.026 (95% CI 0.011–0.057; p < 0.0001; 
I2 67%; Egger’s test 0.439) for abemaciclib.
3.3. Safety results in metastatic and in non-metastatic 
patients
The safety profile was analyzed for metastatic patients and 
for non-metastatic patients. Overall, 19 trials including 3378 
patients were analyzed for the metastatic group, and 5 trials 
including 792 patients for the non-metastatic group 
[18,19,22,26–35,37–53]. Trials with abemaciclib were 
excluded from analysis, because no trials were available in 
a non-metastatic setting [54–58].
Treatment with CDK4/6 inhibitors was associated with 
a similar rate of any grade toxicity (AR 0.981, 95% CI 0.-
973–0.986, p < 0.0001, I2 0% for metastatic patients and AR 
0.990, 95% CI 0.970–0.997, p 0.001, I2 0% for non-metastatic 
patients), with a lower incidence of G3-4 toxicities in the 
non-metastatic group (AR 0.818, 95% CI 0.756–0.867, 
p < 0.0001, I2 88% and AR 0.492, 95% CI 0.413–0.572, 
p 0.852, I2 37% for metastatic and non-metastatic patients, 
respectively).
For any grade neutropenia, AR was of 0.822 (95% CI 0.781–-
0.857; p < 0.0001; I2 84%) and 0.905 (95% CI 0.676–0.977; 
p 0.004; I2 94%) for the metastatic and non-metastatic groups, 
respectively; while for grade 3–4 neutropenia, AR was 0.638 
(95% CI 0,589–0.683; p < 0.0001; I2 84%) for the metastatic and 
0.430 (95% CI 0.358–0.506; p 0.070; I2 59%) for the non- 
metastatic groups.
Figure 4. Absolute risk for any grade diarrhea for palbociclib, ribociclib and abemaciclib.
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Differences in the risk of developing diarrhea were minimal. 
In fact, an AR for any grade diarrhea of 0.181 (95% CI 0.135–-
0.239; p < 0.0001; I2 92%) and of 0.152 (95% CI 0.114–0.199; 
p < 0.0001; I2 28%) was observed for metastatic and non- 
metastatic patients, respectively. The AR for grade 3–4 diar-
rhea was also slightly higher in the metastatic group, with AR 
values of 0.013 (95% CI 0.008–0.020; p < 0.0001; I2 25%) and 
0.009 (95% CI 0.003–0.023; p < 0.0001; I2 0%) in the metastatic 
and non-metastatic groups, respectively.
Publication bias was detected in metastatic patients for any 
grade neutropenia (p 0.001).
3.4. Safety results in pre- and in postmenopausal 
patients
Next, the safety profile was analyzed according to meno-
pausal status. For this analysis, we considered only the 
studies in which menopausal status was declared and in 
which pre- and postmenopausal patients were not mixed. 
Overall, two studies including 427 patients were eligible for 
premenopausal status, and 11 studies including 2117 
patients, were eligible for postmenopausal status [22,26,27,-
,27,31–40,47–53]. Abemaciclib trials were excluded, because 
no trials exclusively in premenopausal status were available 
[54–58].
A single study showed data on all types of toxicities in 
premenopausal patients. In this single study, we observed an 
AR for any grade toxicity and grade 3–4 toxicity of 0.982 (95% 
CI 0.961–0.992) and 0.767 (95% CI 0.719–0.809), respectively. 
In postmenopausal patients, AR for any grade toxicity and G3- 
4 toxicity with random effect models of 0.983 (95% CI 0.974–-
0.988; p < 0.0001; I2 0%) and 0.793 (95% CI 0.664–0.882; 
p < 0.0001; I2 95%) were observed, respectively.
Premenopausal women showed AR for any grade and 
grade 3–4 neutropenia of 0.727 (95% CI 0.609–0.820; 
p < 0.0001; I2 78%) and 0.637 (95% CI 0.590–0.681; 
Figure 5. Absolute risk for grade 3–4 diarrhea for palbociclib, ribociclib and abemaciclib.
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p < 0.0001; I2 0%), respectively. Postmenopausal women 
showed an AR for any grade neutropenia of 0.787 (95% CI 
0.718–0.843; p < 0.0001; I2 88%) and of 0.608 (95% CI 0.541–-
0.670; p 0.002; I2 85%) for grade 3–4 neutropenia.
The AR of developing any grade or grade 3–4 diarrhea 
was 0.174 (95% CI 0.113–0.257; p < 0.0001; I2 0%) and 0.014 
(95% CI 0.006–0.031; p < 0.0001; I2 0%), respectively, in pre- 
menopausal patients, and 0.222 (95% CI 0.170–0.284; 
p < 0.0001; I2 87%) and 0.015 (95% CI 0.009–0.024; 
p < 0.0001; I2 19%), respectively, in postmenopausal 
women.
No publication bias was detected.
3.5. Safety results in previously untreated and in 
pretreated patients
The safety profile was next analyzed in pretreated and in 
previously untreated patients. We included five studies in the 
analysis in previously untreated patients, including 909 
patients, and 14 studies in pretreated patients including 
2469 patients [26–35,37–52]. Studies with abemaciclib were 
studied separately, considering its distinct toxicity profile.
Similar risks of all types of toxicities were observed 
between the two groups: AR 0.987 (95% CI 0.977–0.993; 
p < 0.0001; I2 0%) in previously untreated and AR 0.977 (95% 
CI 0.967–0.984; p < 0.0001; I2 0%) in pretreated for any grade 
toxicity; AR 0.813 (95% CI 0.778–0.844; p < 0.0001; I2 21%) and 
AR 0.814 (95% CI 0.679–0.900; p < 0.0001; I2 94%) for grade 
3–4 toxicity, respectively.
With respect to neutropenia, we observed an AR of 0.794 
(95% CI 0.734–0.843; p < 0.0001; I2 57%) in previously 
untreated patients, an AR of 0.834 (95% CI 0.784–0.875; 
p < 0.0001; I2 87%) in pretreated patients for any grade 
neutropenia and an AR of 0.676 (95% CI 0.576–0.762; 
p 0.001; I2 81%) and of 0.626 (95% CI 0.570–0.679; 
p < 0.0001; I2 84%) for grade 3–4 neutropenia, respectively.
A slightly higher risk of developing diarrhea was observed 
in previously untreated patients. In particular, we observed an 
AR of 0.255 (95% CI 0.179–0.350; p < 0.0001; I2 82%) in pre-
viously untreated and 0.152 (95% CI 0.102–0.222; p < 0.0001; I2 
93%) in pretreated patients for any grade diarrhea, and an AR 
of 0.021 (95% CI 0.013–0.034; p < 0.0001; I2 0%) and 0.009 
(95% CI 0.005–0.015; p < 0.0001; I2 0%) for grade 3–4 diarrhea, 
respectively.
Publication bias was observed in pretreated patients for 
any grade neutropenia (p 0.002).
Trials with abemaciclib were considered separately. 
Overall, two trials including 578 patients were performed in 
pretreated patients, and 1 trial including 328 patients in 
previously untreated patients [54–58]. We were unable to 
perform a meta-analysis in the previously untreated group, 
because only a single trial was available. Overall, we 
observed a higher rate of any grade neutropenia, albeit the 
p-value was not significant, and of grade 3–4 diarrhea in the 
pretreated group. In particular, the AR for any grade neutro-
penia was 0.694 (95% CI 0.238–0.943; p 0.419; I2 98%) in 
pretreated patients vs 0.436 (95% CI 0.383–0.490; p 0.021) 
in previously untreated patients, while for grade 3–4 diarrhea 
it was 0.158 (95% CI 0.106–0.230; p < 0.0001; I2 70%) vs 0.095 
(95% CI 0.067–0.131; p < 0.0001), respectively. Publication 
bias was not evaluable, due to the low number of trials 
analyzed.
4. Discussion
The three CDK4/6 inhibitors palbociclib, ribociclib, and abema-
ciclib showed similar activity in clinical trials and are all 
approved in combination with AI or fulvestrant for treating 
woman with locally advanced or metastatic HR-positive/HER2- 
negative breast cancer as the initial therapy or after failure of 
previous ET. In pre- or peri-menopausal women, ET should be 
associated with a luteinizing hormone release hormone ago-
nist (LHRH). Abemaciclib is also approved by the FDA as 
a monotherapy for treatment of both women and men with 
HR-positive/HER2-negative advanced or metastatic breast can-
cer after progression from ET and chemotherapy based on the 
results of the MONARCH-1 trial [58].
Palbociclib, ribociclib, and abemaciclib have a similar 
mechanism of action and are structurally related. They act by 
binding to the ATP-binding pocket of CDK4 and CDK6, and 
each drug has specific interactions with residues in the ATP- 
binding cleft [59]. They have a different half-maximal inhibi-
tory concentration (IC50) for CDK4 and 6, with consequent 
differences in toxicity profiles. The most common toxicity 
observed with CDK4/6 inhibitors is hematologic, primarily 
due to their action on CDK6, which is a key regulator of 
hematopoietic precursor proliferation [59,60]. Neutropenia fol-
lowing the administration of CDK4/6 inhibitors occurs due to 
a cytostatic effect on the cell cycle in contrast to that induced 
by chemotherapy, which is characterized by DNA damage and 
consequent induction of hematopoietic cell apoptosis [13]. 
CDK4/6 inhibitor-induced neutropenia is quickly reversible 
with the discontinuation of treatment. Therefore, palbociclib 
and ribociclib are administered for three consecutive weeks 
followed by a week’s break, to allow recovery of hematopoie-
tic progenitors. Conversely, abemaciclib can be administered 
continuously. In fact, abemaciclib has a higher affinity for 
CDK4 with an IC50 of 2 nM compared to the IC50 for CDK6, 
which is five-fold higher [61]. Consequently, abemaciclib 
shows a lower rate of hematopoietic toxicity than either pal-
bociclib or ribociclib.
In this analysis, we focused on the most common toxicities 
with CDK4/6 inhibitors. We included in our analysis all studies 
in which CDK4/6 inhibitors were administered at FDA- 
approved doses, including compassionate use programs and 
retrospective real-life clinical cohorts. In this way, we studied 
a population more similar to that treated in daily clinical 
practice without the bias of stringent patient selection in 
clinical trials [62]. The disadvantage of this approach is that 
we found many real-life cohorts for palbociclib, which is the 
oldest of the three drugs, but not for ribociclib and abemaci-
clib, and the inclusion of retrospective cohorts increases the 
heterogeneity between studies. We analyzed the three CDK4/6 
inhibitors separately, unlike in a previous meta-analysis pub-
lished by Costa and colleagues, to compare the safety profiles 
of the three drugs [63]. Although such an analysis does not 
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have the validity of a direct comparison, it is able to collect 
and synthesize all safety data in the literature. Moreover, we 
analyzed all the types of toxicities, not only hematological or 
gastrointestinal toxicities, as in two previously published 
meta-analyses [62,64]. Likewise, our work is distinct from 
another previously published meta-analysis in which the 
authors analyzed only grade 3–4 adverse events because we 
also analyzed low-grade toxicities [65]. Moreover, in our meta- 
analysis, we investigated the two most common toxicities 
(neutropenia and diarrhea) in some subgroups based on 
stage, menopausal status, and line of treatment.
As expected, we observed a higher rate of hematological 
toxicity in the palbociclib and ribociclib groups than in the 
abemaciclib group, which was associated with a low rate of 
severe infections. As expected, we observed a higher rate of 
febrile neutropenia with palbociclib and ribociclib compared 
to abemaciclib, even though it was an uncommon event. 
Abemaciclib showed a higher rate of gastrointestinal toxicity, 
primarily diarrhea, and abdominal pain. Although these 
adverse effects are of low grade in most cases, they have 
a major impact on patient quality of life, unlike neutropenia, 
which is rapidly reversible and not associated with a high rate 
of infection. Compared to palbociclib and abemaciclib, riboci-
clib exhibited a higher rate of hepatic toxicity, respiratory 
toxicity, and QTc prolongation. The latter in particular is 
usually dose-dependent and reversible [13]. However, special 
attention needs to be paid to these toxicities, as they can be 
fatal. Moreover, abemaciclib is associated with a high rate of 
increased creatinine, even though that it was not considered 
a good parameter for assessing renal toxicity. In fact, abema-
ciclib inhibits the secretion of renal tubular transporters, but 
does not affect glomerular function [13,58]. Abemaciclib is 
also associated with a risk of thromboembolic events, 
although this is not reported in our meta-analysis due to 
insufficient data shown in the trials included in the final 
analysis [13].
The results of the subgroup analysis performed in our meta- 
analysis were interesting. These showed an increase of approxi-
mately 33% in the risk of grade 3–4 toxicity of any type and of 
approximately 21% in grade 3–4 neutropenia in metastatic 
patients treated with palbociclib and ribociclib. Pretreated 
patients compared to previously untreated patients receiving 
palbociclib or ribociclib do not appear to have an increased risk 
of developing toxicity, while those receiving abemaciclib 
showed an increase of approximately 26% in neutropenia and 
6% in grade 3–4 diarrhea. Finally, postmenopausal patients 
seem to have a slight increase in risk of approximately 5% for 
developing diarrhea, compared to premenopausal patients. The 
major limitation to this subgroup analysis is the small sample 
size. These results should be confirmed in large prospective 
studies.
5. Expert opinion
The introduction of CDK4/6 inhibitors for the treatment of 
hormone-responsive metastatic breast tumors has significantly 
changed therapeutic algorithms in recent years. The first FDA 
approval was granted to palbociclib in 2017, followed by 
ribociclib and abemaciclib. Currently, one of the primary 
concerns is the choice between these three drugs in individual 
patients.
Although CDK4/6 inhibitors are generally safe and manage-
able drugs, with a low rate of severe complications, specific 
characteristics of their toxicity profile could drive clinical 
choice. Beyond the most common toxicities, hematologic for 
palbociclib and ribociclib, and gastrointestinal for abemaciclib, 
other less frequent adverse events should be considered in 
treatment decisions. In particular, the higher risk of hepatic 
toxicity, QTc prolongation, and respiratory injury for ribociclib 
advises against using these drugs in the presence of lung or 
liver comorbidities or in the presence of concomitant treat-
ment that prolongs the QT interval. Similarly, considering the 
difficulties in easily evaluating renal function by creatinine 
level with the use of abemaciclib, caution advice for the use 
of this drug in specific situations should be posed.
While hazard ratios for progression-free survival (PFS) were 
very similar in all trials comparing CDK4/6 inhibitors plus 
endocrine therapy to placebo plus endocrine therapy, no 
palbociclib trial, two ribociclib trials (MONALEESA-3 and 7) 
and two abemaciclib trials (MONARCH-2 and nextMONARCH) 
showed statistically significant overall survival (OS) differences 
[49,51,54,66]. It is impossible to conclude whether impact on 
OS was influenced by differences in study design, patient 
population, statistical power and/or availability of salvage 
therapy at the different trial centers. No head-to-head com-
parison is currently available for the CDK4/6 inhibitors.
Interestingly, the CDK4/6 inhibitors seem to be even better 
tolerated in early-stage cancer, likely due to the better base-
line clinical condition or to the limited number of treatment 
cycles compared to metastatic patients. For this reason, use of 
these drugs in an early phase seems to be an excellent ther-
apeutic alternative for patient quality of life, to delay the start 
of toxic treatment. None of these drugs are currently approved 
for this indication, but several clinical trials have been pub-
lished or are ongoing. Three clinical trials studied palbociclib 
in the neoadjuvant setting, in combination with letrozole in 
the NeoPAL and in PALLET trials, and in combination with 
anastrozole in the NeoPalAna trial [18,19,22]. Addition of pal-
bociclib to ET enhanced cell cycle arrest without increasing 
the response rate in this setting [18,19,22]. Ribociclib plus 
letrozole showed an efficacy in molecular downstaging by 
PAM50 for HR-positive/HER2-negative patients treated in 
neoadjuvant setting in the CORALLEEN trial [53]. Similarly, in 
the NeoMonarch trial, the association between abemaciclib 
and anastrozole led to a Ki67 reduction in the neoadjuvant 
setting [67].
In light of their efficacy in the metastatic phase and due to 
increase efficacy and delay resistance to adjuvant ET, CKD4/6 
inhibitors are currently being studied in phase III trials after 
surgery: PALLAS (NCT02513394) and PENELOPE 
(NCT01864746) for palbociclib, NATALEE for ribociclib 
(NCT03701334) and MONARCH E for abemaciclib 
(NCT03155997) [68–71]. The results from PALLAS trials were 
recently presented at 2020 ESMO Congress. In this trial, 5760 
patients were randomized to receive adjuvant ET with or with-
out palbociclib, resulting in similar invasive disease-free survi-
val (iDFS) between the two arms [72]. In contrast, the 
MONARCH E trial met the primary endpoint of iDFS with 
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adjuvant abemaciclib plus ET compared to ET alone [73]. 
Long-term follow-up of both trials is extremely important as 
many events in an interim analysis with limited follow-up are 
likely related to patients with primary endocrine resistance, 
and in this context, the reported monotherapy activity of 
abemaciclib may be of importance.
The use of CDK4/6 inhibitors is progressively expanding in 
the field of breast disease. In recent years, several trials have 
been launched to investigate the role of these drugs in other 
settings, such as in other breast cancer subtypes and/or in 
combination with other molecules, such as trastuzumab.
In the monarcHER trial, abemeciclib was studied in associa-
tion with trastuzumab and fulvestrant in heavily pretreated 
HR-positive/HER2-positive locally advanced or metastatic 
breast cancer, resulting in increased PFS compared to stan-
dard chemotherapy plus trastuzumab and demonstrating that 
a chemotherapy-free regimen could be an option in this group 
of patients [16]. Analogously, ribociclib was studied in combi-
nation with trastuzumab in heavily pretreated advanced 
breast cancer in a Phase Ib/II trial, in which 13 patients were 
evaluated for safety [20]. The NA-PHER2 trial investigated the 
combination of palbociclib with pertuzumab, trastuzumab, 
and fulvestrant showing promising results in neoadjuvant set-
ting, with a significant reduction in Ki67 expression [17]. The 
data on triple-negative breast cancer (TNBC) are less convin-
cing, due to the frequent loss of RB that makes this subtype 
less sensitive to CDK4/6 inhibition. However, preclinical data 
suggested that selection based on specific biomarkers could 
lead to identification of patients sensitive to palbociclib. In 
particular, epidermal growth factor receptor (EGFR), its partner 
membrane type-4 matrix metalloproteinase (MT4-MMP), and 
RB are co-expressed in approximately 50% of TNBCs and pre-
dict sensitivity to palbociclib and erlotinib, with additive 
effects from their combination [74]. Moreover, a specific sub-
set of TNBC expressing the androgen receptor (AR), represent-
ing one-third of all TNBC, seems to have proliferative activity 
dependent on CDK4/6 and to be sensitive to CDK4/6 inhibitors 
[75,76]. In this subset of tumors, palbociclib seems to enhance 
the activity of enzalutamide in vitro [77]. A phase I–II trial 
exploring the combination ribociclib-bicalutamide is actually 
being conducted in this group of patients (NCT03090165) [78].
In conclusion, in view of the efficacy and good tolerance 
observed, we think an effort must be made to expand applica-
tion of these drugs to other subtypes and lines of treatment. 
Of course, the highest priority is to define the role of these 
agents in the adjuvant setting with the aim of curing more 
patients.
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